Promentis Pharmaceuticals
Privately-held biopharmaceutical company focused on discovery and clinical development of small-molecule therapeutics for neuropsychiatric disorders. Development efforts center on small-molecule activators of the cystine–glutamate antiporter (System xc-) to restore glutamatergic neurotransmission and address oxidative stress. The company has advanced lead oral candidates through nonclinical programs, completed Phase 1 safety and PK studies, and initiated Phase 2 trials for disorders including trichotillomania.
Industries
Nr. of Employees
small (1-50)
Promentis Pharmaceuticals
Milwaukee, Wisconsin, United States
Patents
Ethyl (2R)-2-acetamido-3-(4-methylbenzoylsulfanyl)propanoate and uses thereof
US-9012674-B1
View Details
Ethyl (2R)-2-acetamido-3-(4-methylbenzoylsulfanyl)propanoate and uses thereof
US-9012674-B1
View DetailsProducts
SXC-2023
Orally administered small-molecule activator of the cystine–glutamate antiporter developed to restore glutamatergic neurotransmission and address oxidative stress in neuropsychiatric disorders; completed Phase 1 SAD and MAD safety/PK studies and progressed into Phase 2 clinical trials (including trichotillomania).
SXC-2023
Orally administered small-molecule activator of the cystine–glutamate antiporter developed to restore glutamatergic neurotransmission and address oxidative stress in neuropsychiatric disorders; completed Phase 1 SAD and MAD safety/PK studies and progressed into Phase 2 clinical trials (including trichotillomania).
Expertise Areas
- Small-molecule CNS drug discovery
- Medicinal chemistry and composition-of-matter IP
- Preclinical pharmacology and toxicology
- Clinical trial management (Phase 1 and Phase 2)
Key Technologies
- Small-molecule therapeutics
- Activation of the cystine–glutamate antiporter (System xc-)
- Preclinical in vivo pharmacology
- Clinical pharmacokinetics (PK) and safety studies
News & Updates
Presentation of psychometric findings from a multi-center trial in trichotillomania.
Overview of results from the company's Phase 2A clinical trial presented at the CNS Summit.
Announcement of successful completion of Phase 1 single and multiple ascending dose studies showing safety, tolerability and consistent PK.
Commencement of Phase 1 single ascending dose study for lead compound and Series C financing details.
Completed 28-patient Phase 2A behavioral biomarker study showing significant improvements in impulse control; 120-patient Phase 2 trichotillomania study fully enrolled.
Received Phase II Small Business Innovation Research award from the National Institute of Mental Health to continue development of novel compounds for schizophrenia.
Presentation of psychometric findings from a multi-center trial in trichotillomania.
Overview of results from the company's Phase 2A clinical trial presented at the CNS Summit.
Announcement of successful completion of Phase 1 single and multiple ascending dose studies showing safety, tolerability and consistent PK.
Commencement of Phase 1 single ascending dose study for lead compound and Series C financing details.
Completed 28-patient Phase 2A behavioral biomarker study showing significant improvements in impulse control; 120-patient Phase 2 trichotillomania study fully enrolled.
Received Phase II Small Business Innovation Research award from the National Institute of Mental Health to continue development of novel compounds for schizophrenia.